Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
CervoMed ( (CRVO) ) has shared an update.
CervoMed Inc. announced that its RewinD-LB Phase 2b trial for dementia with Lewy bodies did not meet primary and secondary endpoints, as target drug concentrations were not achieved. Despite the setback, the safety profile of neflamapimod was favorable, and the company plans to analyze the data further before continuing with future trials. The trial was partially funded by a grant from the National Institutes of Health.
For an in-depth examination of CRVO stock, go to TipRanks’ Stock Analysis page.
